58 results on '"Kümmel, S."'
Search Results
2. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
- Author
-
Kümmel, S., Krocker, J., Kohls, A., Breitbach, G.-P., Morack, G., Budner, M., Blohmer, J.-U., Elling, D., and Kümmel, S
- Subjects
- *
DRUG therapy , *BREAST cancer , *CANCER patients , *PACLITAXEL , *METHOTREXATE , *FLUOROURACIL - Abstract
We evaluated the survival benefit, safety, feasibility, and tolerability of dose-dense (DD) adjuvant chemotherapy with epirubicin and paclitaxel for women with node-positive primary breast cancer. Randomised patients (n=216) received DD or conventional-schedule (CS) chemotherapy. Dose-dense regimen patients (n=108) received epirubicin 90 mg m-2 plus paclitaxel 175 mg m-2 in four 14-day cycles, then cyclophosphamide 600 mg m-2, methotrexate 40 mg m-2, and fluorouracil 600 mg m-2 (CMF 600/40/600) in three 14-day cycles, plus filgrastim 5 microg kg day-1 as growth support in every cycle. Conventional-schedule regimen patients (n=108) received epirubicin 90 mg m-2 plus cyclophosphamide 600 mg m-2 in four 21-day cycles, then CMF 600/40/600 in three 21-day cycles, plus filgrastim if required. After a median follow-up of 38.4 months, 71 patients (33%) relapsed or died: DD, 33 patients (15 deaths); CS, 38 patients (22 deaths). Dose dense showed a trend for improved disease-free survival (DFS) and overall survival (OS). Four-year rates of DFS and OS were 64 and 85% for DD, and 58 and 75% for CS. All seven cycles were administered to 208 patients (96%). Rates of cycle delay, discontinuation, dose reduction, and adverse events were similar in both groups. Dose-dense sequential chemotherapy with epirubicin/paclitaxel then CMF, supported by filgrastim, is safe and improves survival for patients with node-positive breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
3. Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients.
- Author
-
Ataseven, B., Kümmel, S., Weikel, W., Heitz, F., Holtschmidt, J., Lorenz-Salehi, F., Kümmel, A., Traut, A., Blohmer, J., Harter, P., and Bois, A.
- Subjects
- *
BREAST cancer prognosis , *BREAST cancer treatment , *LYMPH nodes , *MOLECULAR biology , *DISEASE progression , *SURGICAL technology , *IMMUNOHISTOCHEMISTRY , *MULTIVARIATE analysis - Abstract
Purpose: Although the impact of lymph node ratio (LNR: ratio of metastatic to resected LNs) in breast cancer (BC) has been investigated, its prognostic value in molecular subtypes remains unclear. Our aim was to evaluate the impact of LNR compared to pN-stage in BC subtypes. Patients/methods: We analyzed the impact of LNR and pN-stage on disease-free (DFS) and overall survival (OS) in 1,656 patients with primary BC who underwent primary axillary surgery (removal of ≥10 LNs) between 1998 and 2011. The cut-off points for LNR were previously published. Using immunohistochemical parameters tumors were grouped in luminalA, luminalB/HER2−, luminalB/HER2+, HER2+ and triple negative (TNBC). Results: For the entire cohort 5/10-year DFS and OS rates were 88/77 % and 88/75 %, respectively. LNR and pN-stage were independent prognostic parameters for DFS/OS in multivariate analysis in the entire cohort and each molecular subgroup ( p < 0.001). However, increasing LNR seemed to discriminated 10-year DFS slightly better than pN-stage in luminalA (intermediate/high LNR 65/44 % versus pN2/pN3 71/53 %), luminalB/HER2− (intermediate/high LNR 48/24 % versus pN2/pN3 41/42 %), and TNBC patients (intermediate/high LNR 49/24 % versus pN2/pN3 56/33 %). Conclusions: LNR is an important prognostic parameter for DFS/OS and might provide potentially more information than pN-stage in different molecular subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Surgical treatment of primary breast cancer in the neoadjuvant setting.
- Author
-
Kümmel, S., Holtschmidt, J., and Loibl, S.
- Subjects
- *
EARLY detection of cancer , *BREAST cancer treatment , *TUMOR growth , *CANCER relapse , *MASTECTOMY ,BREAST cancer chemotherapy - Abstract
Background Neoadjuvant chemotherapy ( NACT) is a standard treatment option for primary operable breast cancer when adjuvant chemotherapy is indicated. Methods This article reviews the use of NACT in breast cancer treatment. Results Pathological complete response ( pCR) rates of up to 60 per cent have been reached for certain breast cancer subgroups. Patients achieving a pCR have a lower locoregional recurrence rate. Nevertheless, the rate of breast-conserving surgery seems to be stable at around 65-70 per cent, although more than 80 per cent of patients respond to NACT. The risk of local relapse does not appear to be higher after NACT, which supports the recommendation to operate within the new margins, as long as there is no tumour in the inked area of the surgical specimen. However, tumours do not shrink concentrically and the re-excision rate is higher after NACT. Mastectomy rates for lobular carcinomas remain high irrespective of tumour response. The role of sentinel lymph node biopsy ( SLNB) in the context of NACT has been studied in recent years, and it is not yet completely clear which type of axillary staging is the most suitable. SLNB before NACT in clinically node-negative patients has been the preferred option. However, this practice is currently changing, and it seems advisable to have the SLNB after NACT to reduce the risk of a false-negative SLNB. Conclusion Overall, patients do benefit from NACT, especially those with human epidermal growth factor receptor 2-positive and triple-negative breast cancer, but surgical/local procedures need to be adapted. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. Frequency Dependence of the Exact Exchange-Correlation Kernel of Time-Dependent Density-Functional Theory.
- Author
-
Thiele, M. and Kümmel, S.
- Subjects
- *
TIME-dependent density functional theory , *KERNEL functions , *EXCITATION energy (In situ microanalysis) , *FREQUENCY dependent capacitors , *NUMERICAL analysis - Abstract
We present a scheme for numerically reconstructing the exact and the Kohn-Sham time-dependent density-density response functions, and from their inverse the numerical representation of the exact frequency-dependent exchange-correlation kernel fxc of time-dependent Kohn-Sham density-functional theory. We investigate the exact fxc in detail for a system that is known to show strong memory effects. The reconstructed kernel fulfills the appropriate sum rule. Using it in linear response calculations, we show how the exact fxc, due to its frequency dependence, yields the exact excitation energies, including the ones of double excitation character. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Orbital Localization, Charge Transfer, and Band Gaps in Semilocal Density-Functional Theory.
- Author
-
Armiento, R. and Kümmel, S.
- Subjects
- *
IONIZATION energy , *IONIZATION (Atomic physics) , *ELECTRON affinity , *CHARGE transfer , *ELECTRON donor-acceptor complexes , *DENSITY functional theory , *MOLECULAR dynamics - Abstract
We derive an exchange energy functional of generalized gradient form with a corresponding potential that changes discontinuously at integer particle numbers. The functional is semilocal, yet incorporates key features that are connected to the derivative discontinuity of Kohn-Sham density-functional theory. We validate our construction for several paradigm systems and explain how it addresses central well-known deficiencies of antecedent semilocal methods, i.e., the description of charge transfer, properly localized orbitals, and band gaps. We find, e.g., an improved shell structure for atoms, eigenvalues that more closely correspond to ionization energies, and an improved description of band structure where localized states are lowered in energy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. Integer particle preference during charge transfer in Kohn-Sham theory.
- Author
-
Hofmann, D. and Kümmel, S.
- Subjects
- *
CHARGE transfer , *ION exchange (Chemistry) , *ELECTROMAGNETIC fields , *DENSITY functionals , *FUNCTIONAL analysis - Abstract
We investigate the static and dynamic charge transfer that is triggered by external electric fields in model molecular wires. A self-interaction correction in Kohn-Sham density functional theory leads to the desired integer electron transfers that do not occur with standard functionals which miss Coulomb blockade effects. Analysis of the multiplicative exchange-correlation potential in stationary cases and during real-time propagation shows how the local exchange-correlation potential builds up step and reverse-step structures that enforce the integer particle preference. The role of spin-symmetry breaking is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
- Author
-
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M, German Breast Group, von Minckwitz, Gunter, Kümmel, Sherko, Vogel, Petra, Hanusch, Claus, Eidtmann, Holger, and Hilfrich, Jörn
- Abstract
Background: Patients with an early response to neoadjuvant chemotherapy have chemosensitive tumors and a high probability for a pathological complete response at surgery. The relationship between extended chemotherapy and pathological complete response at surgery was investigated in a clinical trial.Methods: Untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC). Those whose tumor size decreased by 50% or more by sonographic measurement (ie, reduction in the product of the two largest perpendicular diameters by at least 50%) were classified as responders and randomly assigned to receive four or six more cycles of TAC, for a total of six or eight TAC cycles. The primary aim was to increase the rate of a pathological complete response (defined as no invasive or in situ residual tumor masses in the breast and lymph nodes) from 20% to 26%. Sonographic response rates and rates of breast-conserving surgery and adverse effects were also assessed. All statistical tests were two-sided.Results: Of the 2090 patients in the GeparTrio trial, 1390 (66.5%) were randomly assigned as responders after two initial TAC cycles to receive an additional four (n = 704) or six (n = 686) TAC cycles. Rates of pathological complete response were not statistically significantly different between the arms (21.0% with six TAC cycles and 23.5% with eight TAC cycles; difference = 2.5%, 95% confidence interval [CI] = -1.8% to 6.8%; P = .27). More clinical (48.2% vs 52.9%, difference = 4.7%; 95% CI = -0.55% to 9.95%; P = .08) and sonographic (22.6% vs 27.6%, difference = 5%; 95% CI = 0.45% to 9.55%; P = .033) complete responses at surgery were observed with eight TAC cycles than with six TAC cycles. The rate of breast-conserving surgery was similar in both arms (67.5% vs 68.5%, respectively, P = .68). Grade 3 or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles.Conclusion: Patients receiving eight TAC cycles had statistically significantly higher sonographic response rates but not pathological complete response rates than those receiving six TAC cycles. However, they also had more toxic effects. So far, eight cycles of TAC cannot be recommended for the whole group of patients responding to two initial cycles of TAC. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
9. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
- Author
-
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M, German Breast Group, von Minckwitz, Gunter, Kümmel, Sherko, Vogel, Petra, Hanusch, Claus, Eidtmann, Holger, and Hilfrich, Jörn
- Abstract
Background: Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome. We compared the response of nonresponding patients who continued the same treatment with that of patients who switched to a well-tolerated non-cross-resistant regimen.Methods: Previously untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) per day (TAC). Patients whose tumors did not decrease in size by at least 50% were randomly assigned to four additional cycles of TAC or to four cycles of vinorelbine at 25 mg/m(2) and capecitabine at 2000 mg/m(2) (NX). The outcome was sonographic response, defined as a reduction in the product of the two largest perpendicular diameters by at least 50%. A difference of 10% or less in the sonographic response qualified as noninferiority of the NX treatment. Pathological complete response was defined as no invasive or in situ residual tumor masses in the breast and lymph nodes. Toxic effects were assessed. All statistical tests were two-sided.Results: Of 2090 patients enrolled in the GeparTrio study, 622 (29.8%) who did not respond to two initial cycles of TAC were randomly assigned to an additional four cycles of TAC (n = 321) or to four cycles of NX (n = 301). Sonographic response rate was 50.5% for the TAC arm and 51.2% for the NX arm. The difference of 0.7% (95% confidence interval = -7.1% to 8.5%) demonstrated noninferiority of NX (P = .008). Similar numbers of patients in both arms received breast-conserving surgery (184 [57.3%] in the TAC arm vs 180 [59.8%] in the NX arm) and had a pathological complete response (5.3% vs 6.0%). Fewer patients in the NX arm than in the TAC arm had hematologic toxic effects, mucositis, infections, and nail changes, but more had hand-foot syndrome and sensory neuropathy.Conclusion: Pathological complete responses to both regimens were marginal. Among patients who did not respond to the initial neoadjuvant TAC treatment, similar efficacy but better tolerability was observed by switching to NX than continuing with TAC. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
10. Collectivity in the optical response. of small metal clusters.
- Author
-
Kümmel, S., Andrae, K., and Reinhard, P.-G.
- Subjects
- *
PLASMONS (Physics) , *OSCILLATIONS , *ELECTRONS , *SODIUM - Abstract
The question of whether the linear absorption spectra of metal clusters can be interpreted as density oscillations (collective “plasmons”) or can only be understood as transitions between distinct molecular states is still a matter of debate for clusters with only a few electrons. We calculate the photo-absorption spectra of Na[sub 2] and Na[sub 5] [sup +] comparing two different methods: quantum fluid dynamics and time-dependent density functional theory. The changes in the electronic structure associated with particular excitations are visualized in “snapshots” via transition densities. Our analysis shows that even for the smallest clusters, the observed excitations can be interpreted as intuitively understandable density oscillations. For Na[sub 5] [sup +] , the importance of self-interaction corrections to the adiabatic local density approximation is demonstrated. [ABSTRACT FROM AUTHOR]
- Published
- 2001
11. 201TiP Evaluation of the feasibility of ultrasound-guided clipping of suspicious intramammary lesions in primary breast cancer patients receiving neoadjuvant therapy (Ultra3Detect).
- Author
-
Vlachou, E., Kümmel, S., Künzel, N., Breit, E., Schindowski, D., Pankert, K., Hentsch, S., Hanf, V., Weber, D., Graßhoff, S-T., Müller, C., Lucke, W., Deuschle, P., Engellandt, K., Rüland, A., Dall, P., Harrach, H., Bruzas, S., Chiari, O., and Reinisch, M.
- Subjects
- *
BREAST cancer , *CANCER patients , *CANCER relapse - Published
- 2021
- Full Text
- View/download PDF
12. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
- Author
-
Dent, R., André, F., Gonçalves, A., Martin, M., Schmid, P., Schütz, F., Kümmel, S., Swain, S.M., Bilici, A., Loirat, D., Villalobos Valencia, R., Im, S.-A., Park, Y.H., De Laurentis, M., Colleoni, M., Guarneri, V., Bianchini, G., Li, H., Kirchmayer Machackova, Z., and Mouta, J.
- Subjects
- *
TRIPLE-negative breast cancer , *CLINICAL trials , *IMMUNOTHERAPY , *ATEZOLIZUMAB , *PROGRAMMED death-ligand 1 , *IMMUNE checkpoint inhibitors , *TUMOR classification , *HORMONE receptor positive breast cancer , *CANCER relapse - Abstract
Immune checkpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic triple-negative breast cancer (aTNBC), but randomised data in rapidly relapsing aTNBC are scarce. IMpassion132 (NCT03371017) enrolled patients with aTNBC relapsing <12 months after last chemotherapy dose (anthracycline and taxane required) or surgery for early TNBC. PD-L1 status was centrally assessed using SP142 before randomisation. Initially patients were enrolled irrespective of PD-L1 status. From August 2019, enrolment was restricted to PD-L1-positive (tumour immune cell ≥1%) aTNBC. Patients were randomised 1:1 to placebo or atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy until disease progression or unacceptable toxicity. Stratification factors were chemotherapy regimen (carboplatin plus gemcitabine or capecitabine monotherapy), visceral (lung and/or liver) metastases and (initially) PD-L1 status. The primary endpoint was overall survival (OS), tested hierarchically in patients with PD-L1-positive tumours and then, if positive, in the modified intent-to-treat (mITT) population (all-comer patients randomised pre-August 2019). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and safety. Among 354 patients with rapidly relapsing PD-L1-positive aTNBC, 68% had a disease-free interval of <6 months and 73% received carboplatin/gemcitabine. The OS hazard ratio was 0.93 (95% confidence interval 0.73-1.20, P = 0.59; median 11.2 months with placebo versus 12.1 months with atezolizumab). mITT and subgroup results were consistent. Median PFS was 4 months across treatment arms and populations. ORRs were 28% with placebo versus 40% with atezolizumab. Adverse events (predominantly haematological) were similar between arms and as expected with atezolizumab plus carboplatin/gemcitabine or capecitabine following recent chemotherapy exposure. OS, which is dismal in patients with TNBC relapsing within <12 months, was not improved by adding atezolizumab to chemotherapy. A biology-based definition of intrinsic resistance to immunotherapy in aTNBC is urgently needed to develop novel therapies for these patients in next-generation clinical trials. • Data on outcomes in patients with rapidly relapsing TNBC are scarce. • The phase III IMpassion132 trial enrolled patients with TNBC relapse <12 months after chemotherapy/surgery for early TNBC. • OS was not improved by adding atezolizumab to chemotherapy for rapidly relapsing PD-L1-positive TNBC. • Patients with rapidly relapsing TNBC have a dismal prognosis and represent a population with huge unmet need. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. 172P Gene expression in early breast cancer (EBC) patients (pts) with relapse despite pathologic complete response (pCR): An intra- and interindividual (matched control) analysis.
- Author
-
Bruzas, S., Kümmel, S., Harbeck, N., Schmid, P., Cortés, J., Seiberling, C., Chiari, O., Harrach, H., Ataseven, B., Dyson, M., Traut, E., Theuerkauf, I., Gebauer, D., Gluz, O., and Reinisch, M.
- Subjects
- *
BREAST cancer , *GENE expression - Published
- 2020
- Full Text
- View/download PDF
14. Malignant melanoma metastatic to the breast: an interdisciplinary challenge.
- Author
-
Kümmel S, Förster H, Fiedler B, Kretschmer J, and Elling D
- Published
- 2004
- Full Text
- View/download PDF
15. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
- Author
-
Pusztai, L., Denkert, C., O'Shaughnessy, J., Cortes, J., Dent, R., McArthur, H., Kümmel, S., Bergh, J., Park, Y.H., Hui, R., Harbeck, N., Takahashi, M., Untch, M., Fasching, P.A., Cardoso, F., Zhu, Y., Pan, W., Tryfonidis, K., and Schmid, P.
- Subjects
- *
PEMBROLIZUMAB , *TRIPLE-negative breast cancer , *TRACHELECTOMY , *NEOADJUVANT chemotherapy , *CENTRAL nervous system , *PROGNOSIS - Abstract
KEYNOTE-522 demonstrated statistically significant improvements in pathological complete response (pCR) with neoadjuvant pembrolizumab plus chemotherapy and event-free survival (EFS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with high-risk, early-stage triple-negative breast cancer (TNBC). Prior studies have shown the prognostic value of the residual cancer burden (RCB) index to quantify the extent of residual disease after neoadjuvant chemotherapy. In this preplanned exploratory analysis, we assessed RCB distribution and EFS within RCB categories by treatment group. A total of 1174 patients with stage T1c/N1-2 or T2-4/N0-2 TNBC were randomized 2 : 1 to pembrolizumab 200 mg or placebo every 3 weeks given with four cycles of paclitaxel + carboplatin, followed by four cycles of doxorubicin or epirubicin + cyclophosphamide. After surgery, patients received pembrolizumab or placebo for nine cycles or until recurrence or unacceptable toxicity. Primary endpoints are pCR and EFS. RCB is a prespecified exploratory endpoint. The association between EFS and RCB was assessed using a Cox regression model. Pembrolizumab shifted patients into lower RCB categories across the entire spectrum compared with placebo. There were more patients in the pembrolizumab group with RCB-0 (pCR), and fewer patients in the pembrolizumab group with RCB-1, RCB-2, and RCB-3. The corresponding hazard ratios (95% confidence intervals) for EFS were 0.70 (0.38-1.31), 0.92 (0.39-2.20), 0.52 (0.32-0.82), and 1.24 (0.69-2.23). The most common first EFS events were distant recurrences, with fewer in the pembrolizumab group across all RCB categories. Among patients with RCB-0/1, more than half [21/38 (55.3%)] of all events were central nervous system recurrences, with 13/22 (59.1%) in the pembrolizumab group and 8/16 (50.0%) in the placebo group. Addition of pembrolizumab to chemotherapy resulted in fewer EFS events in the RCB-0, RCB-1, and RCB-2 categories, with the greatest benefit in RCB-2. These findings demonstrate that pembrolizumab not only increased pCR rates, but also improved EFS among most patients who do not have a pCR. • KEYNOTE-522 evaluated neoadjuvant pembrolizumab + chemotherapy/adjuvant pembrolizumab versus neoadjuvant chemotherapy alone in early TNBC. • Neoadjuvant pembrolizumab + chemotherapy/adjuvant pembrolizumab significantly improved pCR/EFS versus neoadjuvant chemotherapy alone. • We explored the effect of adding pembrolizumab to chemotherapy on outcomes by RCB category. • Pembrolizumab not only increased pCR rates, but also improved EFS among many patients who do not have a pCR. • Findings support neoadjuvant pembrolizumab + chemotherapy/adjuvant pembrolizumab as a standard of care treatment in early TNBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. 323PSubcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis.
- Author
-
Kümmel, S, Tondini, C A, Abraham, J, Nowecki, Z I, Itrych, B, Hitre, E, Karaszewska, B, Juarez, A, Morales-Vásquez, F, and García, J M Pérez
- Subjects
- *
TRASTUZUMAB , *BREAST cancer , *HORMONE receptor positive breast cancer , *EMPLOYEE ownership , *ABIRATERONE acetate , *RESEARCH grants - Published
- 2018
- Full Text
- View/download PDF
17. Fluorescence quenching in an organic donor-acceptor dyad: A first principles study.
- Author
-
Körzdörfer, T., Tretiak, S., and Kümmel, S.
- Subjects
- *
FLUORESCENCE , *PERYLENE , *BENZANTHRACENES , *SOLAR cells , *LIGHT emitting diodes - Abstract
Perylene bisimide and triphenyl diamine are prototypical organic dyes frequently used in organic solar cells and light emitting devices. Recent Förster-resonant-energy-transfer experiments on a bridged organic dyad consisting of triphenyl diamine as an energy-donor and perylene bisimide as an energy-acceptor revealed a strong fluorescence quenching on the perylene bisimide. This quenching is absent in a solution of free donors and acceptors and thus attributed to the presence of the saturated CH2O(CH2)12-bridge. We investigate the cause of the fluorescence quenching as well as the special role of the covalently bound bridge by means of time dependent density functional theory and molecular dynamics. The conformational dynamics of the bridged system leads to a charge transfer process between donor and acceptor that causes the acceptor fluorescence quenching. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
18. Phase I/II Trial of primary chemotherapy with non-pegylated liposomal doxorubicin, paclitaxel and lapatinib in patients with HER2-positive, early stage breast cancer.
- Author
-
Aktas, B., Kümmel, S., Krocker, J., Elling, D., Lantzsch, T., Bischoff, J., Fersis, N., Böhme, M., Belau, A. K., Lampe, D., and Schmid, P.
- Subjects
- *
BREAST cancer research , *BREAST cancer patients , *BREAST cancer risk factors , *TRASTUZUMAB , *ANTHRACYCLINES , *PACLITAXEL - Abstract
Background: Several studies showed that pathologic complete response (pCR) is a surrogate for disease free survival (DFS) and overall survival (OS). Combinations of trastuzumab and anthracyclines in HER2-positive breast cancer are highly active but associated with a high incidence of cardiotoxicity. The risk of cardiac damage can be significantly reduced through liposomal encapsulation of anthracyclines. This phase I/II study was initiated to evaluate the combination of non-pegylated liposomal doxorubicin (NPLD), paclitaxel and lapatinib as primary treatment for patients with early stage, HER2-positive primary breast cancer. Patients and Methods: Patients with newly diagnosed HER2-positive (IHC 3+ or FISH+) early stage (T1c N1-2 or T2 N0-2) breast cancer were treated with NPLD (60mg/m²; day 1), paclitaxel (175mg/m², day 1) and lapatinib (750-1500 mg orally daily) in 3-week intervals for up to 6 cycles. The primary endpoints were dose-limiting toxicities (DLT) and pathological complete response (pCR). Secondary endpoints include safety, incidence of cardiac events, and clinical response. Exploratory endpoints include molecular markers for sensitivity or resistance to chemotherapy and/or lapatinib evaluated. Results: A total of 84 patients have been included. No dose-limiting toxicity were observed and the maximum tolerated doses were NPLD 60mg/m², paclitaxel 175mg/m² and lapatinib 1500mg. Recommended phase 2 doses (P2D) were NPLD 60mg/m², paclitaxel 175mg/m² and lapatinib 1250mg. The treatment was generally well tolerated and associated with toxicities that were consistent with the known side-effects of the individual agents. No cardiac event has been observed to date. Preliminary efficacy data confirm a pCR breast rate of 41.7% and pCR rate in breast and lymph nodes of 37.5%, in 32 evaluable patients treated at ≥ P2D. Conclusions: The combination of NPLD, paclitaxel and lapatinib is well tolerated and has high antitumor activity in patients with HER2-positive primary breast cancer. Updated results of all 84 patients will be presented. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
19. 217 (PB-041) Poster - Prospective, Multi-Center, Artificial Intelligence Study for Early Prediction of Serious Events under Treatment Is Now Open for Recruitment in Breast Cancer - OMCAT Trial in Progress.
- Author
-
Tonk, C.H., Kates, R.E., Kümmel, S., Cardoso, F., Schinköthe, T., Harbeck, N., Staib, P., and Schmidt, A.
- Subjects
- *
RESEARCH , *ARTIFICIAL intelligence , *CONFERENCES & conventions , *BREAST tumors , *LONGITUDINAL method - Published
- 2022
- Full Text
- View/download PDF
20. Predicting photoemission intensities and angular distributions with real-time density-functional theory.
- Author
-
Dauth, M. and Kümmel, S.
- Subjects
- *
PHOTOEMISSION , *ANGULAR distribution (Nuclear physics) , *DENSITY functional theory - Abstract
Photoemission spectroscopy is one of the most frequently used tools for characterizing the electronic structure of condensed matter systems. We discuss a scheme for simulating photoemission from finite systems based on time-dependent density-functional theory. It allows for the first-principles calculation of relative electron binding energies, ionization cross sections, and anisotropy parameters. We extract these photoemission spectroscopy observables from Kohn-Sham orbitals propagated in real time. We demonstrate that the approach is capable of estimating photoemission intensities, i.e., peak heights. It can also reliably predict the angular distribution of photoelectrons. For the example of benzene we contrast calculated angular distribution anisotropy parameters to experimental reference data. Self-interaction free Kohn-Sham theory yields meaningful outer valence single-particle states in the right energetic order. We discuss how to properly choose the complex absorbing potential that is used in the simulations. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
21. 275P A phase II study of LAG525 in combination with spartalizumab (PDR001), PDR001 and carboplatin (Carbo), or Carbo, as first- or second-line therapy in patients (Pts) with advanced (Adv) triple-negative breast cancer (tnbc).
- Author
-
Carey, L.A., Pierga, J-Y., Kümmel, S., Jerusalem, G., De Laurentiis, M., Miller, M., Li, Z., Kaper, M., Su, F., and Loi, S.
- Subjects
- *
TRIPLE-negative breast cancer , *CARBOPLATIN - Published
- 2021
- Full Text
- View/download PDF
22. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
- Author
-
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Untch, M., Fasching, P. A., Cardoso, F., Andersen, J., Patt, D., Danso, M., Ferreira, M., and Mouret-Reynier, M.-A.
- Abstract
BACKGROUND The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery in an earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy. The primary results regarding event-free survival in this trial have not been reported. METHODS We randomly assigned, in a 2:1 ratio, patients with previously untreated stage II or III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks plus paclitaxel and carboplatin, followed by four cycles of pembrolizumab or placebo plus doxorubicin--cyclophosphamide or epirubicin--cyclophosphamide. After definitive surgery, patients received adjuvant pembrolizumab (pembrolizumab--chemotherapy group) or placebo (placebo--chemotherapy group) every 3 weeks for up to nine cycles. The primary end points were pathological complete response (the results for which have been reported previously) and event-free survival, defined as the time from randomization to the date of disease progression that precluded definitive surgery, local or distant recurrence, occurrence of a second primary cancer, or death from any cause. Safety was also assessed. RESULTS Of the 1174 patients who underwent randomization, 784 were assigned to the pembrolizumab--chemotherapy group and 390 to the placebo--chemotherapy group. The median follow-up at this fourth planned interim analysis (data cutoff, March 23, 2021) was 39.1 months. The estimated event-free survival at 36 months was 84.5% (95% confidence interval [CI], 81.7 to 86.9) in the pembrolizumab--chemotherapy group, as compared with 76.8% (95% CI, 72.2 to 80.7) in the placebo--chemotherapy group (hazard ratio for event or death, 0.63; 95% CI, 0.48 to 0.82; P<0.001). Adverse events occurred predominantly during the neoadjuvant phase and were consistent with the established safety profiles of pembrolizumab and chemotherapy. CONCLUSIONS In patients with early triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab after surgery, resulted in significantly longer event-free survival than neoadjuvant chemotherapy alone. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
- Author
-
Eiermann, W., Rezai, M., Kümmel, S., Kühn, T., Warm, M., Friedrichs, K., Schneeweiss, A., Markmann, S., Eggemann, H., Hilfrich, J., Jackisch, C., Witzel, I., Eidtmann, H., Bachinger, A., Hell, S., and Blohmer, J.
- Subjects
- *
BREAST cancer treatment , *ADJUVANT treatment of cancer , *ESTROGEN receptors , *CANCER relapse , *HER2 gene , *LYMPH nodes , *LONGITUDINAL method ,BREAST cancer chemotherapy - Abstract
Background We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC). Patients and methods A total of 379 eligible women with estrogen receptor positive (ER+), HER2-negative EBC and 0–3 positive lymph nodes were enrolled. Treatment recommendations, patients' decisional conflict, physicians' confidence before and after knowledge of the RS and actual treatment data were recorded. Results Of the 366 assessable patients 244 were node negative (N0) and 122 node positive (N+). Treatment recommendations changed in 33% of all patients (N0 30%, N+ 39%). In 38% of all patients (N0 39%, N+ 37%) with an initial recommendation for chemoendocrine therapy, the post-RS recommendation changed to endocrine therapy, in 25% (N0 22%, N+ 39%) with an initial recommendation for endocrine therapy only to combined chemoendocrine therapy, respectively. A patients' decisional conflict score improved by 6% (P = 0.028) and physicians' confidence increased in 45% (P < 0.001) of all cases. Overall, 33% (N0 29%, N+ 38%) of fewer patients actually received chemotherapy as compared with patients recommended chemotherapy pre-test. Using the test was cost-saving versus current clinical practice. Conclusion RS-guided chemotherapy decision-making resulted in a substantial modification of adjuvant chemotherapy usage in node-negative and node-positive ER+ EBC. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
24. Gold-platinum alloys and Vegard's law on the nanoscale.
- Author
-
Leppert, L., Albuquerque, R. Q., and Kümmel, S.
- Subjects
- *
GOLD-platinum alloys , *NANOSTRUCTURED materials , *X-ray diffraction , *X-ray scattering , *NUMERICAL calculations - Abstract
The structure of gold-platinum nanoparticles is heavily debated as theoretical calculations predict core-shell particles, whereas x-ray diffraction experiments frequently detect randomly mixed alloys. By calculating the structure of gold-platinum nanoparticles with diameters of up to ≈3.5 nm and simulating their x-ray diffraction patterns, we show that these seemingly opposing findings need not be in contradiction: Shells of gold are hardly visible in usual x-ray scattering, and the interpretation of Vegard's law is ambiguous on the nanoscale. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
25. Kohn-Sham Self-Interaction Correction in Real Time.
- Author
-
Hofmann, D., Körzdörfer, T., and Kümmel, S.
- Subjects
- *
DENSITY functionals , *GENERALIZATION , *APPROXIMATION theory , *MATHEMATICAL optimization , *PHYSICS -- Bibliographies , *ELECTRONIC excitation - Abstract
We present a solution scheme for the time-dependent Kohn-Sham self-interaction correction. Based on the generalized optimized effective potential approach, the multiplicative Kohn-Sham potential is constructed in real time and real space for the self-interaction corrected local density approximation. Excitations of different character, including charge-transfer excitations that had been regarded as prime examples for the failure of standard time-dependent density functionals, are described correctly by this approach. We analyze the time-dependent exchange-correlation potential and density, revealing features that are decisive for the correct description of the response. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
26. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
- Author
-
Hahn S, Heusner T, Kümmel S, Köninger A, Nagarajah J, Müller S, Boy C, Forsting M, Bockisch A, Antoch G, Stahl A, Hahn, Steffen, Heusner, Till, Kümmel, Sherko, Köninger, Angelika, Nagarajah, James, Müller, Stefan, Boy, Christian, Forsting, Michael, and Bockisch, Andreas
- Subjects
- *
POSITRON emission tomography , *DIAGNOSTIC imaging , *BONE metastasis , *BREAST cancer , *NUCLEAR medicine , *MAGNETIC resonance imaging - Abstract
Background: Bone scintigraphy is the standard procedure for the detection of bone metastases in breast cancer patients. FDG-PET/CT has been reported to be a sensitive tool for tumor staging in different malignant diseases. However, its accuracy for the detection of bone metastases has not been compared to bone scintigraphy.Purpose: To compare whole-body FDG-PET/CT and bone scintigraphy for the detection of bone metastases on a lesion basis in breast cancer patients.Material and Methods: Twenty-nine consecutive women (mean age 58 years, range 35-78 years) with histologically proven breast cancer were assessed with bone scintigraphy and whole-body FDG-PET/CT. Twenty-one patients (72%) were suffering from primary breast cancer and eight patients (28%) were in aftercare with a history of advanced breast cancer. Both imaging procedures were assessed for bone metastases by a radiologist and a nuclear medicine physician. Concordant readings between bone scintigraphy and FDG-PET/CT were taken as true. Discordant readings were verified with additional MRI imaging in all patients and follow-up studies in most patients.Results: A total of 132 lesions were detected on bone scintigraphy, FDG-PET/CT or both. According to the reference standard, 70/132 lesions (53%) were bone metastases, 59/132 lesions (45%) were benign, and three lesions (2%) remained unclear. The sensitivity of bone scintigraphy was 76% (53/70) compared to 96% (67/70) for FDG-PET/CT. The specificity of bone scintigraphy and FDG-PET/CT was 95% (56/59) and 92% (54/59), respectively. According to the reference standard bone metastases were present in eight out of the 29 patients (28%), whereas 20 patients (69%) were free of bone metastases. One (3%) patient had inconclusive readings on both modalities as well as on MRI and follow-up studies. Bone scintigraphy and FDG-PET/CT correctly identified seven out of eight patients with bone metastases and 20 out of 20 patients free of metastases.Conclusion: On a lesion-basis whole-body FDG-PET/CT is more sensitive and equally specific for the detection of bone metastases compared with bone scintigraphy. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
27. Real-time elastography--an advanced method of ultrasound: First results in 108 patients with breast lesions.
- Author
-
Thomas, A., Fischer, T., Frey, H., Ohlinger, R., Grunwald, S., Blohmer, J.-U., Winzer, K.-J., Weber, S., Kristiansen, G., Ebert, B., Kümmel, S., and Kümmel, S
- Subjects
- *
MEDICAL imaging systems , *PATIENTS , *BREAST , *PRECANCEROUS conditions , *CANCER , *ANATOMY , *DIAGNOSIS - Abstract
Objectives: To evaluate whether real-time elastography, a new, non-invasive method for the diagnosis of breast cancer, improves the differentiation and characterization of benign and malignant breast lesions.Methods: Real-time elastography was carried out in 108 potential breast tumor patients with cytologically or histologically confirmed focal breast lesions (59 benign, 49 malignant; median age, 53.9 years; range, 16-84 years). Tumor and healthy tissue were differentiated by measurement of elasticity based on the correlation between tissue properties and elasticity modulus. Evaluation was performed using the three-dimensional (3D) finite element method, in which the information is color-coded and superimposed on the B-mode ultrasound image. A second observer evaluated the elastography images, in order to improve the objectivity of the method. The results of B-mode scan and elastography were compared with those of histology and previous sonographic findings. Sensitivities and specificities were calculated, taking histology as the gold standard.Results: B-mode ultrasound had a sensitivity of 91.8% and a specificity of 78%, compared with sensitivities of 77.6% and 79.6% and specificities of 91.5% and 84.7%, respectively, for the two observers evaluating elastography. Agreement between B-mode ultrasound and elastography was good, yielding a weighted kappa of 0.67.Conclusions: Our initial clinical results suggest that real-time elastography improves the specificity of breast lesion diagnosis and is a promising new approach for the diagnosis of breast cancer. Elastography provides additional information for differentiating malignant BI-RADS (breast imaging reporting and data system) category IV lesions. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
28. 299 (PB-115) Poster - Improved Chemosensitivity Prediction for HR+HER2- Breast Cancer Patients with MammaPrint High2 risk group in the FLEX Trial.
- Author
-
O'Shaughnessy, J., Sonnenblick, A., Strulov Shachar, S., Kümmel, S., Fischer, L.A., Rezek, D., Pronin, D., Menicucci, A., and Audeh, W.
- Subjects
- *
RISK assessment , *HORMONE receptor positive breast cancer , *CHEMORECEPTORS , *CANCER patients , *CONFERENCES & conventions , *ONCOGENES - Published
- 2024
- Full Text
- View/download PDF
29. 5LBA LBA Mini Oral - Significant higher satisfaction with breast and psychosocial well-being and low complication rate – First report of the 24 months follow-up results from the prospective international mesh-supported pre-pectoral breast reconstruction trial (PRO-Pocket-Trial clinicaltrials.gov: NCT03868514)
- Author
-
Paepke, S., Klein, E., Andrulat, A., Ankel, C., Bauer, L., Faridi, A., Fink, V., Gerber-Schäfer, C., Gschwantler-Kaulich, D., Heil, J., Kümmel, S., Ohlinger, R., and Thill, M.
- Subjects
- *
MAMMAPLASTY , *CONFERENCES & conventions , *PATIENT satisfaction , *WELL-being , *SURGICAL meshes - Published
- 2024
- Full Text
- View/download PDF
30. Pembrolizumab for Early Triple-Negative Breast Cancer.
- Author
-
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., and Dent, R.
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *RESEARCH , *CLINICAL trials , *CARBOPLATIN , *DOXORUBICIN , *RESEARCH methodology , *MONOCLONAL antibodies , *ANTINEOPLASTIC agents , *EVALUATION research , *MEDICAL cooperation , *TUMOR classification , *COMPARATIVE studies , *CYCLOPHOSPHAMIDE , *EPIRUBICIN , *KAPLAN-Meier estimator , *RESEARCH funding , *PACLITAXEL , *COMBINED modality therapy , *BREAST tumors - Abstract
Background: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear.Methods: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population.Results: At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively.Conclusions: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
31. Communication: Tailoring the optical gap in light-harvesting molecules.
- Author
-
Karolewski, A., Stein, T., Baer, R., and Kümmel, S.
- Subjects
- *
BAND gaps , *PROTEINS , *CHARGE transfer , *ELECTRONIC excitation , *DENSITY functionals , *EMPIRICAL research , *ELECTRON donor-acceptor complexes , *LIGHT absorption - Abstract
Systematically varying the optical gap that is associated with charge-transfer excitations is an important step in the design of light-harvesting molecules. So far the guidance that time-dependent density functional theory could give in this process was limited by the traditional functionals' inability to describe charge-transfer excitations. We show that a nonempirical range-separated hybrid approach allows to reliably predict charge-transfer excitations for molecules of practically relevant complexity. Calculated absorption energies agree with measured ones. We predict from theory that by varying the number of thiophenes in donor-acceptor-donor molecules, the energy of the lowest optical absorption can be tuned to the lower end of the visible spectrum. Saturation sets in at about five thiophene rings. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
32. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC.
- Author
-
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y.H., Hui, R., Harbeck, N., Takahashi, M., Untch, M., Fasching, P.A., Cardoso, F., Ding, Y., Tryfonidis, K., Aktan, G., Karantza, V., and O'Shaughnessy, J.
- Subjects
- *
ADJUVANT treatment of cancer , *TRIPLE-negative breast cancer , *PEMBROLIZUMAB , *CANCER chemotherapy , *PLACEBOS , *CANCER treatment - Published
- 2021
- Full Text
- View/download PDF
33. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
- Author
-
Loibl, S, Untch, M, Burchardi, N, Huober, J, Sinn, B V, Blohmer, J -U, Grischke, E -M, Furlanetto, J, Tesch, H, Hanusch, C, Engels, K, Rezai, M, Jackisch, C, Schmitt, W D, Minckwitz, G von, Thomalla, J, Kümmel, S, Rautenberg, B, Fasching, P A, and Weber, K
- Subjects
- *
TRIPLE-negative breast cancer , *METASTATIC breast cancer - Abstract
Background Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC). Therefore, we evaluated the addition of durvalumab to standard neoadjuvant chemotherapy (NACT) in primary TNBC. Patients and methods GeparNuevo is a randomised phase II double-blind placebo-controlled study randomising patients with TNBC to durvalumab or placebo given every 4 weeks in addition to nab-paclitaxel followed by standard EC. In the window-phase durvalumab/placebo alone was given 2 weeks before start of nab-paclitaxel. Randomisation was stratified by stromal tumour-infiltrating lymphocyte (sTILs). Patients with primary cT1b-cT4a-d disease, centrally confirmed TNBC and sTILs were included. Primary objective was pathological complete response (pCR) (ypT0 ypN0). Results A total of 174 patients were randomised, 117 participated in the window-phase. Median age was 49.5 years (range 23–76); 47 patients (27%) were younger than 40 years; 113 (65%) had stage ≥IIA disease, 25 (14%) high sTILs, 138 of 158 (87%) were PD-L1-positive. pCR rate with durvalumab was 53.4% (95% CI 42.5% to 61.4%) versus placebo 44.2% (95% CI 33.5% to 55.3%; unadjusted continuity corrected χ 2 P = 0.287), corresponding to OR = 1.45 (95% CI 0.80–2.63, unadjusted Wald P = 0.224). Durvalumab effect was seen only in the window cohort (pCR 61.0% versus 41.4%, OR = 2.22, 95% CI 1.06–4.64, P = 0.035; interaction P = 0.048). In both arms, significantly increased pCR (P < 0.01) were observed with higher sTILs. There was a trend for increased pCR rates in PD-L1-positive tumours, which was significant for PD-L1-tumour cell in durvalumab (P = 0.045) and for PD-L1-immune cell in placebo arm (P = 0.040). The most common immune-related adverse events were thyroid dysfunction any grade in 47%. Conclusions Our results suggest that the addition of durvalumab to anthracycline-/taxane-based NACT increases pCR rate particularly in patients treated with durvalumab alone before start of chemotherapy. Trial registration ClinicalTrials.gov number: NCT02685059. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto.
- Author
-
Loibl, S, Weber, K E, Timms, K M, Elkin, E P, Hahnen, E, Fasching, P A, Lederer, B, Denkert, C, Schneeweiss, A, Braun, S, Salat, C T, Rezai, M, Blohmer, J U, Zahm, D M, Jackisch, C, Gerber, B, Klare, P, Kümmel, S, Schem, C, and Paepke, S
- Abstract
Background In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD). Patients and methods Patients were randomized to paclitaxel plus nonpegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin (PMCb). The secondary study end points disease-free survival (DFS) and overall survival (OS) were analyzed. Median follow-up was 47.3 months. HRD was among the exploratory analyses in GeparSixto and was successfully measured in formalin-fixed, paraffin-embedded tumor samples of 193/315 (61.3%) participants with TNBC. Homologous recombination (HR) deficiency was defined as HRD score ≥42 and/or presence of tumor BRCA mutations (tm BRCA). Results A significantly better DFS (hazard ratio 0.56, 95% CI 0.34–0.93; P = 0.022) was observed in patients with TNBC when treated with PMCb. The improvement of OS with PMCb was not statistically significant. Additional carboplatin did not improve DFS or OS in patients with HER2-positive tumors. HR deficiency was detected in 136 (70.5%) of 193 triple-negative tumors, of which 82 (60.3%) showed high HRD score without tm BRCA. HR deficiency independently predicted pCR (ypT0 ypN0) [odds ratio (OR) 2.60, 95% CI 1.26–5.37, P = 0.008]. Adding carboplatin to PM significantly increased the pCR rate from 33.9% to 63.5% in HR deficient tumors (P = 0.001), but only marginally in HR nondeficient tumors (from 20.0% to 29.6%, P = 0.540; test for interaction P = 0.327). pCR rates with carboplatin were also higher (63.2%) than without carboplatin (31.7%; OR 3.69, 1.46–9.37, P = 0.005) in patients with high HRD score but no tm BRCA. DFS rates were improved with addition of carboplatin, both in HR nondeficient (hazard ratio 0.44, 0.17–1.17, P = 0.086) and HR deficient tumors (hazard ratio 0.49, 0.23–1.04, P = 0.059). Conclusions The addition of carboplatin to neoadjuvant PM improved DFS significantly in TNBC. Long-term survival analyses support the neoadjuvant use of carboplatin in TNBC. HR deficiency in TNBC and HRD score in non-tm BRCA TNBC are predictors of response. HRD does not predict for carboplatin benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
35. 41 (PB-041) Poster - Underestimated risk of involved margins in Skin (SMM)- and Nipple Sparing Mastectomies (NSM) – Data and Multimodal Approach for Improvement.
- Author
-
Paepke, S., Andrulat, A., Ankel, C., Bauer, L., Baumann, K., Blohmer, J.U., Faridi, A., Fink, V., Gerber-Schäfer, C., Gschwantler-Kaulich, D., Heil, J., Kümmel, S., Mau, C., Kossmann-Meiré, A., Ohlinger, R., and Thill, M.
- Subjects
- *
CONFERENCES & conventions , *SURGICAL margin , *RISK assessment , *QUALITY assurance , *LUMPECTOMY - Published
- 2022
- Full Text
- View/download PDF
36. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
- Author
-
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., and Weber, K.
- Subjects
- *
TRIPLE-negative breast cancer , *NEOADJUVANT chemotherapy , *BIOMARKERS , *HISTORICAL source material - Published
- 2022
- Full Text
- View/download PDF
37. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
- Author
-
Loibl, S., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Wiebringhaus, H., Kümmel, S., Warm, M., Paepke, S., Just, M., Hanusch, C., Hackmann, J., Blohmer, J.-U., Clemens, M., Dan Costa, S., Gerber, B., Engels, K., Nekljudova, V., and von Minckwitz, G.
- Subjects
- *
BREAST cancer , *TRASTUZUMAB , *RANDOMIZED controlled trials , *CYCLOPHOSPHAMIDE , *CANCER patients , *THERAPEUTICS - Abstract
Background: The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solventbased paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin, and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2+breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2+tumors from the GeparSepto trial (n=396) in comparison to the HER2-cohort. Patients and methods: Patients with histologically confirmed breast cancer (n=1206) received four cycles of weekly paclitaxel [either solvent-based (Pac) or nab-paclitaxel (nab-Pac), according to randomization] followed by 4 cycles of epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 q3w, with concurrent trastuzumab and pertuzumab q3w for those with HER2+tumors. The primary endpoint was pCR defined as ypT0 ypN0. Results: Higher rates of pCR were achieved in HER2+than in HER2-tumors (57.8% versus 22.0%, P<0.0001), with the highest rate in the HER2+/HR-cohort (71.0%; 66.7% Pac, 74.6% nab-Pac). In HER2+/HR+tumors, the pCR rate was 52.9% (49.7% Pac, 56.4% nab-Pac). Grade≥3 toxic effects were significantly more common in HER2+than in HER2-patients, with grade 3-4 diarrhea in 7.6% versus 0.9% (P<0.001) and febrile neutropenia in 6.3% versus 3.3% (P=0.023) of patients. Left ventricular ejection fraction decreases from baseline were uncommon, with 2.0% versus 0.4% of patients showing decreases to<50% along with a≥10% decrease from baseline. Conclusion: In HER2+early breast cancer, a dual HER2-targeted combination of pertuzumab and trastuzumab, together with taxane-epirubicin-cyclophosphamide neoadjuvant chemotherapy, achieved high rates of pCR. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
38. 216 (PB-040) Poster - AI-based smartphone App using a single-lead ECG for automated QTc diagnostics in oncology.
- Author
-
Tonk, C.H., Schinköthe, T., Harbeck, N., Carmelo, V., Gomes Feliciano, J., Wuerstlein, R., Kümmel, S., and Schmidt, A.
- Subjects
- *
LONG QT syndrome diagnosis , *MOBILE apps , *ARTIFICIAL intelligence , *CONFERENCES & conventions , *SHORT QT syndrome , *ELECTROCARDIOGRAPHY , *AUTOMATION , *ONCOLOGY - Published
- 2022
- Full Text
- View/download PDF
39. 40 (PB-040) Poster - Mesh-Pocket Supported Prepectoral Direct-to-Implant Breast Reconstruction: Preliminary Results of a Prospective Analysis.
- Author
-
Paepke, S., Klein, E., Andrulat, A., Ankel, C., Bauer, L., Faridi, A., Fink, V., Gerber-Schäfer, C., Gschwantler-Kaulich, D., Heil, J., Kümmel, S., Ohlinger, R., and Thill, M.
- Subjects
- *
MAMMAPLASTY , *CONFERENCES & conventions , *PECTORALIS muscle , *BREAST implants , *TREATMENT effectiveness , *SURGICAL meshes , *EVALUATION - Published
- 2022
- Full Text
- View/download PDF
40. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).
- Author
-
von Minckwitz, G., Rezai, M., Tesch, H., Huober, J., Gerber, B., Zahm, D.M., Hilfrich, J., Costa, S.D., Dubsky, P., Blohmer, J.U., Denkert, C., Hanusch, C., Jackisch, C., Kümmel, S., Fasching, P.A., Schneeweiss, A., Paepke, S., Untch, M., Burchardi, N., and Mehta, K.
- Subjects
- *
ANTHRACYCLINES , *ANTINEOPLASTIC agents , *BREAST tumors , *COMBINED modality therapy , *CONFIDENCE intervals , *DRUG resistance in cancer cells , *HYDROCARBONS , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *EARLY medical intervention , *DESCRIPTIVE statistics , *ZOLEDRONIC acid - Abstract
Background Patients with invasive residual disease after neoadjuvant chemotherapy (NACT) are considered to have chemo-resistant breast cancer. Bisphosphonates are an established treatment for bone metastases and are of potential benefit as adjuvant treatment in early breast cancer. Patients and methods Patients who had invasive tumour residuals (ypT1-4 and/or ypN+) after a minimum of four cycles of anthracycline-taxane-containing NACT were eligible for the NeoAdjuvant Trial Add-oN study. Patients were randomised within 3 years after surgery to receive zoledronate 4 mg i.v. for 5 years versus observation. Zoledronate was given every 4 weeks for the first 6 months, every 3 months for the following 2 years, and every 6 months for the last 2.5 years. Primary objective was disease-free survival. Results After a median time of 54.7 months no difference in disease-free survival was observed between the zoledronate and observation groups (hazard ratio [HR] 0.960, 95% confidence interval [CI] 0.709–1.30, log rank P = 0.789). Various subgroups were examined without identifying a treatment effect of zoledronate. Patients over 55 years of age showed a HR of 0.832 in favour of zoledronate, but the result was not significant ( P = 0.480). A similar result was obtained for overall survival with a HR of 1.19 (95% CI 0.79–1.79; log rank P = 0.408). Zoledronate was well tolerated and no new toxicity signal was identified. Conclusion Postneoadjuvant treatment with zoledronate does not improve outcome in patients without pathological complete response after neoadjuvant anthracycline-taxane-based chemotherapy for early breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. 247P Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study.
- Author
-
Decker, T., Fasching, P.A., Nusch, A., Hartkopf, A., Heinrich, B.J., Kurbacher, C.M., Fuchs, R., Tesch, H., Krabisch, P., Huober, J., Kümmel, S., Brucker, S.Y., Janni, W., Schneeweiss, A., Schuler, M., Fehm, T.N., Lüftner, D., C. Quiering, Kreuzeder, J., and Reinisch, M.
- Subjects
- *
BREAST cancer , *LETROZOLE , *ESTROGEN , *SAFETY - Published
- 2021
- Full Text
- View/download PDF
42. 208P ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC.
- Author
-
Schmid, P., Gomez-Pardo, P., Wheatley, D., Roy, P., Krabisch, P., Thill, M., Ledwidge, S., Thompson, A., Macaskill, E.J., Viehstädt, N., Purushotham, A., Gluz, O., Stefek, A., Ackerman, C., Prendergast, A., Mousa, K., Jones, L., Viale, G., Cortés, J., and Kümmel, S.
- Subjects
- *
THERAPEUTICS - Published
- 2021
- Full Text
- View/download PDF
43. 138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC).
- Author
-
Swain, S.M., Tan, A., Gianni, L., Kümmel, S., Dang, C., Schneeweiss, A., O'Shaughnessy, J., Liu, H., Aguila, C., Heeson, S., Macharia, H., Restuccia, E., and Loibl, S.
- Subjects
- *
HER2 positive breast cancer , *SUBCUTANEOUS injections , *TRASTUZUMAB , *ANAPHYLAXIS , *ALLERGIES - Published
- 2021
- Full Text
- View/download PDF
44. The use of ultrasonic cavitation for near-surface structuring of robust and low-cost AlNi catalysts for hydrogen production.
- Author
-
Cherepanov, P. V., Melnyk, I., Skorb, E. V., Fratzl, P., Zolotoyabko, E., Dubrovinskaia, N., Dubrovinsky, L., Avadhut, Y. S., Senker, J., Leppert, L., Kümmel, S., and Andreeva, D. V.
- Subjects
- *
ULTRASONICS , *ALUMINUM catalysts , *NICKEL catalysts , *HYDROGEN production , *SHOCK waves , *ALLOYS - Abstract
Ultrasonically induced shock waves stimulate intensive interparticle collisions in suspensions and create large local temperature gradients in AlNi particles. These trigger phase transformations at the surface rather than in the particle interior. We show that ultrasonic processing is an effective approach for developing the desired compositional gradients in nm-thick interfacial regions of metal alloys and formation of effective catalysts toward the hydrogen evolution reaction. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
45. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro).
- Author
-
von Minckwitz, G., Rezai, M., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., Hanusch, C., Blohmer, J. U., Costa, S. D., Jackisch, C., Paepke, S., Schneeweiss, A., Kümmel, S., Denkert, C., Mehta, K., Loibl, S., and Untch, M.
- Subjects
- *
BREAST cancer treatment , *CANCER chemotherapy , *TRASTUZUMAB , *ANTHRACYCLINES , *EPIDERMAL growth factor , *CYCLOPHOSPHAMIDE , *EPIRUBICIN - Abstract
1495 breast cancer patients received either neoadjuvant EC-Docetaxel or EC-Doxetaxel plus capecitabine or EC-Docetaxel followed by capecitabine and simultaneous trastuzumab in HER2-positive disease. Consistently with pCR rates, adding capecitabine does not improve disease-free survival, but patients with HER2-positive disease showed better overall survival than patients with HER2-negative disease.Background The GeparQuattro study showed that adding capecitabine or prolonging the duration of anthracycline-taxane-based neoadjuvant chemotherapy from 24 to 36 weeks did not increase pathological complete response (pCR) rates. Trastuzumab-treated patients with HER2-positive disease showed a higher pCR rate than patients with HER2-negative disease treated with chemotherapy alone. We here present disease-free (DFS) and overall survival (OS) analyses. Patients and methods Patients (n = 1495) with cT ≥ 3 tumors, or negative hormone-receptor status, or positive hormone-receptor and clinically node-positive disease received four times epirubicin/cyclophosphamide and were thereafter randomly assigned to four times docetaxel (Taxotere), or four times docetaxel/capecitabine over 24 weeks, or four times docetaxel followed by capecitabine over 36 weeks. Patients with HER2-positive tumors received 1 year of trastuzumab, starting with the first chemotherapy cycle. Follow-up was available for a median of 5.4 years. Results Outcome was not improved for patients receiving capecitabine (HR 0.92; P = 0.463 for DFS and HR 93; P = 0.618 for OS) as well as for patients receiving 36 weeks of chemotherapy (HR 0.97; P = 0.818 for DFS and HR 0.97; P = 0.825 for OS). Trastuzumab-treated patients with HER2-positive disease showed similar DFS (P = 0.305) but a significantly better adjusted OS (P = 0.040) when compared with patients with HER2-negative disease treated with chemotherapy alone. Recorded long-term cardiac toxicity was low. Conclusions Long-term results, similar to the results of pCR, do not support the use of capecitabine in the neoadjuvant setting in addition to an anthracycline-taxane-based chemotherapy. However, the results support previous data showing a benefit of trastuzumab as predicted by higher pCR rates. Clinical trial number NCT 00288002, www.clinicaltrials.gov. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
46. DeterminingExcitation-Energy Transfer Times and Mechanismsfrom Stochastic Time-Dependent Density Functional Theory.
- Author
-
Hofmann-Mees, D., Appel, H., Di Ventra, M., and Kümmel, S.
- Subjects
- *
EXCITATION energy (In situ microanalysis) , *ENERGY transfer , *STOCHASTIC analysis , *TIME-dependent density functional theory , *NUMERICAL calculations , *MOLECULAR self-assembly - Abstract
We developed an approach for calculatingexcitation-energy transfertimes in supermolecular arrangements based on stochastic time-dependentdensity functional theory (STDDFT). The combination of real-time propagationand the stochastic Schrödinger equation with a Kohn–ShamHamiltonian allows for simulating how an excitation spreads throughan assembly of molecular systems. The influence that approximations,such as the dipole–dipole coupling approximation of Förstertheory, have on energy-transfer times can be checked explicitly. Asa first application of our approach we investigate a light-harvesting-inspiredmodel ring system, calculating the time it takes for an excitationto travel from one side of the ring to the opposite side under idealand perturbed conditions. Among other things we find that completelyremoving a molecule from the ring may inhibit energy transfer lessthan having an energetically detuned molecule in the ring. In addition,Förster’s dipole coupling approximation may noticeablyoverestimate excitation-energy transfer efficiency. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
47. 21 - Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer.
- Author
-
Rutgers, E.J.T., van 't Veer, L., Poncet, C., Cardozo, J.Lopes, Delaloge, S., Pierga, J.Y., Vuylsteke, P., Brain, E., Viale, G., Kümmel, S., Rubio, I., Zoppoli, G., Thompson, A., Zaman, K., Knox, S., Hilbers, F., Peric, A., Meulemans, B., Piccart, M., and Cardoso, F.
- Subjects
- *
BREAST tumor treatment , *CANCER chemotherapy , *CONFERENCES & conventions , *GENE expression profiling - Published
- 2020
- Full Text
- View/download PDF
48. Coordination-driven magnetic-to-nonmagnetic transition in manganese-doped silicon clusters.
- Author
-
Zamudio-Bayer, V., Leppert, L., Hirsch, K., Langenberg, A., Rittmann, J., Kossick, M., Vogel, M., Richter, R., A. Terasaki, Möller, T., Issendorff, B. v., Kümmel, S., and Lau, J. T.
- Subjects
- *
MAGNETIC transitions , *MAGNETISM , *PHASE transitions , *MANGANESE , *TRANSITION metals , *SILICON - Abstract
The interaction of a single manganese impurity with silicon is analyzed in a combined experimental and theoretical study of the electronic, magnetic, and structural properties of manganese-doped silicon clusters. The structural transition from exohedral to endohedral doping coincides with 3d electron derealization and a quenching of high-spin states. For all geometric structures investigated, we find a correlation of the magnetic moment with the manganese coordination number and nearest-neighbor distance. This observation can be generalized to manganese point defects in bulk silicon, whose magnetic moments fall within the observed magnetic-to-nonmagnetic transition, and therefore react very sensitively to changes in the local geometry. The results indicate that high-spin states in manganese-doped silicon could be stabilized by an appropriate lattice expansion. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
49. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: Results of a companion protocol of the randomized, NOGGO–AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy
- Author
-
Braicu, E.I., Fotopoulou, C., Chekerov, R., Richter, R., Blohmer, J., Kümmel, S., Stamatian, F., Yalcinkaya, I., Mentze, M., Lichtenegger, W., and Sehouli, J.
- Subjects
- *
SERUM , *VASCULAR endothelial growth factors , *CERVICAL cancer treatment , *TREATMENT effectiveness , *CANCER radiotherapy , *MEDICAL protocols , *ADJUVANT treatment of cancer , *CISPLATIN - Abstract
Abstract: Objective: Aim of the present study was to analyze the expression-profile of IGF1, IGFBP3, sICAM1, sVCAM1, MMP2, MMP9, TIMP2, VEGFA, VEGFD, VEGFC and VEGFR1 in patients with high-risk FIGO-stage Ib-IIb cervical cancer. Methods: Serum from 68 cervical cancer patients treated within a phase-III-trial with either simultaneous cisplatin radiochemotherapy or sequential systemic carboplatin and paclitaxel followed by percutaneous irradiation was analyzed by ELISA. Both target expression and correlation with important clinicopathological factors were analyzed following standard statistic procedures. Results: All 68 patients underwent a primary radical hysterectomy with pelvic and/or paraaortic lymphadenectomy. 85.3% of the extirpated tumors had clear surgical margins (R0). Increased levels of VEGFR1, TIMP2 and MMP2 were significantly associated with positive surgical margins (p =0.004, p =0.018 and p =0.004, respectively). High concentration of MMP2 and TIMP2 correlated additionally with an advanced age at time of diagnosis (p =0.001 and p =0.007, respectively). For the cut-off value of 100pg/ml, an increased VEGFR1 was significantly associated with poor overall (OS) and progression-free (PFS) survival (p =0.017 and p =0.015, respectively). A TIMP2 concentration of lower than 90ng/ml was significantly associated with poorer OS and PFS (p =0.009 and p =0.043, respectively). In the multivariate analysis, TIMP2 expression in serum was the only independent prognostic factor for OS (p =0.032, HR=6.51, 95% CI=1.17–36.01). Conclusions: Expression-profile of specific biomarkers associated with tumor invasion, cell migration and angiogenesis seems to be of prognostic value for both OS and PFS in patients undergoing surgery due to primary cervical cancer. Further analyses are warranted to allow an implementation of such markers into clinical practice. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
50. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.
- Author
-
Schmid, Peter, Krocker, J., Kreienberg, R., Klare, P., Kittel, K., Sommer, H., Heinrich, G., Steck, T., Lichtenegger, W., Elling, D., and Kümmel, S.
- Subjects
- *
DOXORUBICIN , *BREAST cancer treatment , *CANCER patients , *ANTHRACYCLINES , *TOXICITY testing - Abstract
Non-pegylated liposomal doxorubicin (NPLD) has demonstrated equivalent antitumor activity to conventional doxorubicin and a significantly lower risk of cardiotoxicity when given as single agent or in combination with cyclophosphamide, but there is limited experience with the combination of NPLD and taxanes. This phase II study was performed to evaluate the efficacy and safety of the NPLD and docetaxel in patients with metastatic breast cancer. A total of 51 patients were treated with NPLD (60 mg/m2) and docetaxel (75 mg/m2) in 3-weeks intervals for up to eight cycles. The overall response rate was 50% and 78% of patients derived a clinical benefit. Median time to progression and overall survival were 10.0 months (95% CI, 6.9–13.1 months) and 25 months (95% CI, 22.1–29.8 months), respectively. Median duration of response was 12.0 months (95% CI 7.1–16.9). The treatment was generally well tolerated and associated with toxicities that were consistent with the known side-effects of the individual agents and of anthracycline/taxane combinations. There were no symptomatic cardiac averse events and mild asymptomatic LVEF changes were reported in five patients. The combination of NPLD and docetaxel is well tolerated and has high antitumour activity in MBC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.